scholarly journals AIDS Vaccine Development: Challenges and Opportunities Edited by Wayne C. Koff, Patricia Kahn, and Ian D. Gust Norwich, United Kingdom: Caister Academic Press, 2007. 151 pp., illustrated. $99.00 (paper)

2007 ◽  
Vol 45 (3) ◽  
pp. 407-407
Author(s):  
G. P. Wormser ◽  
C. L. Cooper
Keyword(s):  
United Kingdom ◽  
Vaccine Development ◽  
Academic Press ◽  
Aids Vaccine ◽  
Challenges And Opportunities

AIDS Vaccine Development: Challenges and Opportunities

2007 ◽  
Vol 1 (1) ◽  
pp. 29-33
Author(s):  
Saladin Osmanov ◽  
Marie Paule Kieny
Keyword(s):  
Vaccine Development ◽  
Aids Vaccine ◽  
Challenges And Opportunities

scholarly journals Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom

2021 ◽  
pp. 174077452110247
Author(s):  
M Estée Török ◽  
Benjamin R Underwood ◽  
Mark Toshner ◽  
Claire Waddington ◽  
Emad Sidhom ◽  
...  
Keyword(s):  
United Kingdom ◽  
Vaccine Development ◽  
Research Training ◽  
Vaccine Trial ◽  
Lessons Learned ◽  
Rapid Diagnostics ◽  
Use Of Technology ◽  
Wide Range ◽  
Challenges And Opportunities ◽  
Set Up

The COVID-19 pandemic has resulted in unprecedented challenges for healthcare systems worldwide. It has also stimulated research in a wide range of areas including rapid diagnostics, novel therapeutics, use of technology to track patients and vaccine development. Here, we describe our experience of rapidly setting up and delivering a novel COVID-19 vaccine trial, using clinical and research staff and facilities in three National Health Service Trusts in Cambridgeshire, United Kingdom. We encountered and overcame a number of challenges including differences in organisational structures, research facilities available, staff experience and skills, information technology and communications infrastructure, and research training and assessment procedures. We overcame these by setting up a project team that included key members from all three organisations that met at least daily by teleconference. This group together worked to identify the best practices and procedures and to harmonise and cascade these to the wider trial team. This enabled us to set up the trial within 25 days and to recruit and vaccinate the participants within a further 23 days. The lessons learned from our experiences could be used to inform the conduct of clinical trials during a future infectious disease pandemic or public health emergency.

Live Recombinant Vectors for AIDS Vaccine Development

2003 ◽  
Vol 3 (3) ◽  
pp. 273-284 ◽  
Author(s):  
Rebecca Voltan ◽  
Marjorie Robert-Guroff
Keyword(s):  
Vaccine Development ◽  
Aids Vaccine ◽  
Recombinant Vectors
Sign in / Sign up

Export Citation Format

Share Document